How were ARMO BioSciences' earnings last quarter?

ARMO BioSciences, Inc. (NASDAQ:ARMO) posted its quarterly earnings data on Monday, April, 2nd. The company reported ($9.62) EPS for the quarter, missing analysts' consensus estimates of ($0.45) by $9.17.

What other stocks do shareholders of ARMO BioSciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ARMO BioSciences investors own include Standex International (SXI) , Exelixis (EXEL) , Tesla (TSLA) , NVIDIA (NVDA) , AbbVie (ABBV) , Alibaba Group (BABA) , Bausch Health Companies (BHC) , EyePoint Pharmaceuticals (EYPT) , Madrigal Pharmaceuticals (MDGL) and Progenics Pharmaceuticals (PGNX) .

When did ARMO BioSciences IPO?

ARMO BioSciences (ARMO) raised $100 million in an IPO on Friday, January 26th 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Jefferies, Leerink Partners and BMO Capital Markets acted as the underwriters for the IPO and Baird was co-manager.

NASDAQ:ARMO

ARMO BioSciences (ARMO) Stock Price, News & Analysis

→ IRS Loophole Gives Americans An Escape From Inflation (From Birch Gold) (Ad)

Free ARMO Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: $49.98
▼
$49.98
50-Day Range: $49.98
▼
$49.98
52-Week Range: $25.10
▼
$57.19

Volume: N/A
Average Volume: 201,363 shs
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get ARMO BioSciences alerts:

Ad Birch Gold

IRS Loophole Gives Americans An Escape From Inflation

In the years immediately following 2008-09, as the economy stagnated, gold exploded in value. Today, Goldman Sachs is telling its clients that gold may reach $2,250 within the next few years. Don't miss your chance to diversify your savings.

Request your info kit on gold now

About ARMO BioSciences Stock (NASDAQ:ARMO)

ARMO BioSciences, Inc., an immuno-oncology company, develops a pipeline of novel product candidates that activate the immune system of cancer patients to recognize and eradicate tumors in the United States. Its lead product candidate is AM0010, a long acting form of human interleukin-10 that is in Phase III randomized pivotal clinical trial for the treatment of pancreatic ductal adenocarcinoma. The company is also developing AM0010 that has completed Phase I/Ib clinical trial for the treatment of non-small cell lung cancer, renal cell carcinoma, colorectal cancer, and melanoma and breast cancer. In addition, it is developing AM0001, a monoclonal antibody against programmed cell death protein-1 checkpoint inhibitor; AM0015, a recombinant human interleukin-15; AM0012, a recombinant human Interleukin-12; and AM0003, a monoclonal antibody against leukocyte activating gene-3 protein program. The company was formerly known as Targenics, Inc. and changed its name to ARMO BioSciences, Inc. in December 2012. ARMO BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.

Ad Birch Gold

IRS Loophole Gives Americans An Escape From Inflation

Request your info kit on gold now

ARMO Stock News Headlines

February 3, 2024 | morningstar.com

Pacific Biosciences of California Inc

December 1, 2023 | msn.com

Pedro Pascal Gets Realistic Fantastic Four Armor As Reed Richards In Stunning MCU Art

April 18, 2024 | Birch Gold (Ad)

IRS Loophole Gives Americans An Escape From Inflation

November 6, 2023 | finance.yahoo.com

Caribou Biosciences Announces Appointment of Sundar Jagannath, MD, to its Scientific Advisory Board

October 14, 2023 | msn.com

5 Sizzling Well-Known Stocks Under $10 With Giant Upside Potential

July 21, 2023 | forbes.com

Armor Protective Packaging

May 28, 2023 | msn.com

Best Armor Sets In V Rising, Ranked

May 11, 2023 | investing.com

Codiak BioSciences Inc (CDAKQ)

April 18, 2024 | Birch Gold (Ad)

IRS Loophole Gives Americans An Escape From Inflation

February 18, 2023 | msn.com

Pedro Pascal Has A Candid Confession About The Mandalorian Armor

February 15, 2023 | msn.com

Pedro Pascal's Mandalorian Suit Is Way Clumsier To Wear In Real-Life Than On TV

February 14, 2023 | msn.com

Pedro Pascal Gets Asked About What It's Like To Wear The Mandalorian Armor And Gave A Very Honest Response

January 22, 2023 | finance.yahoo.com

Novadip Biosciences SA Appoints Judy Ashworth, MD, as Chief Medical Officer

January 12, 2023 | finance.yahoo.com

Boehringer Ingelheim and 3T Biosciences Join Forces to Develop Next-Generation Cancer Immunotherapies

January 2, 2023 | msn.com

How To Find All Wraith Lairs In Immortals Fenyx Rising

December 14, 2022 | marketwatch.com

Myocarditis Treatment Market Growth Share 2023 | Research by Future Prospects, Opportunities and Challenges, Key Dynamics and Size Forecast to 2028

August 19, 2022 | chron.com

Texas company hopes to 'de-extinct' Tasmanian tiger in next 10 years

August 18, 2022 | nz.finance.yahoo.com

HR Acuity Named to Inc. 5000 Annual List

August 13, 2022 | reuters.com

Eli Lilly and Co

August 8, 2022 | businessinsider.com

9 top West Coast biotechs that VCs say are poised to take off in the next year

August 2, 2022 | entrepreneur.com

2 Stocks That Could Be Long-Term Winners for Investors

July 19, 2022 | finance.yahoo.com

Insilico Medicine Appoints Sujata Rao, M.D., as Senior Vice President to Oversee Clinical Development

July 14, 2022 | msn.com

How to craft Hollowfang Battlegear in V Rising

July 11, 2022 | msn.com

How To Farm Pristine Hide In V Rising

July 8, 2022 | msn.com

Metal Gear Rising: Revengeance - How To Beat GRAD

July 6, 2022 | msn.com

How to use console commands in V Rising

July 4, 2022 | msn.com

Rising of the Shield Hero Season 2's Finale Is a Disappointing End

See More Headlines

Receive ARMO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ARMO BioSciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 4/02/2018
Today: 4/18/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical Preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:ARMO
CUSIP: N/A
CIK: 1693664
Web: www.armobio.com
Phone: 650-779-5075
Fax: N/A
Employees: N/A
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: N/A

The 10 Best AI Stocks to Own in 2024

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

Dr. Peter Van Vlasselaer (Age 59)
Founder, Pres, CEO & Director
Mr. Herbert C. Cross (Age 46)
Chief Financial Officer
Dr. Joseph Leveque (Age 57)
Chief Medical Officer
Dr. Martin Oft (Age 51)
Founder and VP of Pre-Clinical & Clinical Devel.
Dr. Russell T. Kawahata (Age 64)
VP of Technical Operations

Key Competitors

View All Competitors

ARMO Stock Analysis - Frequently Asked Questions

How were ARMO BioSciences' earnings last quarter?: ARMO BioSciences, Inc. (NASDAQ:ARMO) posted its quarterly earnings data on Monday, April, 2nd. The company reported ($9.62) EPS for the quarter, missing analysts' consensus estimates of ($0.45) by $9.17.
What other stocks do shareholders of ARMO BioSciences own?: Based on aggregate information from My MarketBeat watchlists, some companies that other ARMO BioSciences investors own include Standex International (SXI), Exelixis (EXEL), Tesla (TSLA), NVIDIA (NVDA), AbbVie (ABBV), Alibaba Group (BABA), Bausch Health Companies (BHC), EyePoint Pharmaceuticals (EYPT), Madrigal Pharmaceuticals (MDGL) and Progenics Pharmaceuticals (PGNX).
When did ARMO BioSciences IPO?: ARMO BioSciences (ARMO) raised $100 million in an IPO on Friday, January 26th 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Jefferies, Leerink Partners and BMO Capital Markets acted as the underwriters for the IPO and Baird was co-manager.

This page (NASDAQ:ARMO) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

ARMO BioSciences (ARMO) Stock Price, News & Analysis

About ARMO BioSciences Stock (NASDAQ:ARMO)

ARMO Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

ARMO Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info